Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.

Ursula A. Matulonis,Ronnie Shapira-Frommer,Alessandro D. Santin,Alla Sergeevua Lisyanskaya,Sandro Pignata,Ignace Vergote,Francesco Raspagliesi,Gabe S. Sonke,Michael J. Birrer,Diane Provencher,Jalid Sehouli,Nicoletta Colombo,Antonio González-Martín,Ana Oaknin,Petronella B. Ottevanger,Vilius Rudaitis,Kia Katchar,Zhen Wang,Jane Ruman,Jonathan A. Ledermann

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study.

2018

5511Background: Data from the KEYNOTE-028 study (NCT02054806) suggested that pembrolizumab (pembro) has clinical activity in patients (pts) with PD-L1+ advanced ovarian cancer (AOC). We assessed th...

Keywords:

Interim
Oncology
advanced ovarian cancer
Recurrent Ovarian Cancer
Medicine
Pembrolizumab
Internal medicine
Pathology
antitumor activity
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations